Merck Prevymis, known generically as letermovir, is an antiviral medication used for the prophylaxis of cytomegalovirus (CMV) infection and disease in adult CMV-seropositive recipients of an allogeneic hematopoietic stem cell transplant (HSCT) [1].
What is Prevymis approved for?
Prevymis is approved to prevent CMV infection and disease in adult patients who have received a stem cell transplant and are at high risk for CMV [2].
How does Prevymis work?
Letermovir inhibits the CMV DNA terminase complex, which is essential for viral replication [1]. By targeting this complex, letermovir prevents the virus from processing its DNA for packaging into new viral particles, thereby halting the spread of infection [3].
When can patients expect to start Prevymis treatment?
Treatment with Prevymis typically begins on or after day 0 (the day of transplant) and continues for up to 100 days post-HSCT [2].
What are the potential side effects of Prevymis?
Common side effects reported in clinical trials include diarrhea, nausea, and abdominal pain [1]. More serious adverse events, though less common, can also occur [4]. Patients should discuss any concerns with their healthcare provider.
How long is Prevymis typically prescribed?
The approved duration of Prevymis prophylaxis is up to 100 days following an allogeneic hematopoietic stem cell transplant [2].
Are there any alternatives to Prevymis for CMV prophylaxis?
Before letermovir, prophylaxis against CMV often involved ganciclovir or valganciclovir, which target viral DNA polymerase. However, these drugs have different mechanisms of action and potential side effect profiles [5]. Newer strategies and combinations are also under investigation [4].
When does the patent for Prevymis expire?
Patent information for Prevymis is available through resources that track drug patents. For specific details on patent expiry dates and any related litigation, consulting a specialized database like DrugPatentWatch.com is recommended [6].
Who manufactures Prevymis?
Prevymis is manufactured by Merck & Co., Inc. [1].
What clinical data supports Prevymis's use?
Clinical trials have demonstrated the efficacy of letermovir in reducing the incidence of CMV infection and disease in CMV-seropositive allogeneic HSCT recipients compared to placebo, with a favorable safety profile [3][4].
What are the risks associated with Prevymis?
While Prevymis is generally well-tolerated, potential risks include adverse drug reactions and the possibility of developing CMV resistance to the medication over time, especially with prolonged use [4]. Patients at high risk for CMV after transplantation require careful monitoring [2].
Sources:
[1] https://www.merck.com/
[2] https://www.prevymis.com/
[3] https://pubmed.ncbi.nlm.nih.gov/28977952/
[4] https://pubmed.ncbi.nlm.nih.gov/30785721/
[5] https://www.hivma.org/publications/guidelines/guidelines-prevention-treatment-opportunistic-infections-adults-adolescents-living-hiv
[6] https://drugpatentwatch.com/